Skip to main content

Table 1 Patient characteristics

From: Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease

  UC CD
N 15 25
Gender (n)   
   Female 4 11
   Male 11 14
Age median (range) 25 (16-57) 33 (18-51)
Disease duration (y) (median, range) 1-40 (10,7) 1-25 (9,6)
Smokers 0 0
Disease severity (UCDAI, HB) (n)   
   Mild 1  
   Moderate 13  
   Severe   
   >5 in HB (range)   24 (5-27)
Previous medication (n)   
   Aminosalicylates 15 25
   Glucocorticosteroids 15 25
   Immunomodulators (6-MP/AZA) 15 25
   Infliximab   9
   Antibiotics 12 23
Patients with extraintestinal manifestations (n) 4 12
Patients with previous abdominal surgery for IBD (n) 4 6
Patients with perianal fistulas (n)   5
Disease location   
   Extensive 6  
   Left side 7  
   Proctitis 2  
   Extensive colonic   21
   Small bowel + colonic   1
   Esofagus + small bowel   1
   Stomach + small bowel + colonic   1
  1. UCDAI score of 3 to 6 is defined as mild, 7 to 10 as moderate and 11 to 12 as severe UC.
  2. HB score ≥ 5 defined as active CD